| Helvepharm AG - Rivastigmin Zentiva Patch 9.5 mg/24 h, transdermales Pflaster |
| 62917 | | 02 | | Rivastigmin Zentiva Patch 9.5 mg/24 h | | transdermales Pflaster | | N06DA03 | | Rivastigmin | | 27.03.2014 | | |
|
| Composition |
| rivastigminum 13.8 mg, 2-ethylhexylis acrylatis et vinylis acetatis polymerisatum, polyisobutylenum, silica colloidalis anhydrica, paraffinum perliquidum, Trägermaterial: polyethylenum et polyesterum et aluminium metallicum, Drucktinte (Orange): ad praeparationem pro 9.2 cm², cum liberatione 9.5 mg/24h. |
| Packungsbestandteile |
| Timbre transdermique | | | | | Principe actif | Concentr. |
|---|
| Rivastigmine | 13.8 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Rivastigmine | 13.8 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| 2-ethylhexylis Acrylatis | | | | Aluminium Metallicum | | | | Cum Liberatione | 9.5mg / 24h | | | Drucktinte (Orange): ad Praeparationem | 9.2 cm | | | Paraffine Perliquide | | | | Polyesterum | | | | Polyethylène | | Trägermaterial | | Polyisobutylenum | | | | Silica Colloidalis Anhydrica | | | | Vinylis Acetatis Polymerisatum | | |
| |
|
|
